603168.SHG Zhejiang Shapuaisi Pharmaceutical Co Ltd
- Market cap
- CNY 1.91B
- P/E
- -
- P/B
- 1.47x
- ROE
- -6.8%
- Dividend yield
- 0.42%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603168.SHG undervalued?
Graham numberThe Graham number of Zhejiang Shapuaisi Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Shapuaisi Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Shapuaisi Pharmaceutical Co Ltd yet.
Zhejiang Shapuaisi Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Shapuaisi Pharmaceutical Co Ltd
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antimicrobials, gynecology, and other classes. It offers its products in injections, oral solutions, eye drops, large-volume injections, oral solutions, tablets, granules, and other dosage forms. It also offers medical and health care, and scientific research and teaching facilities. Zhejiang …
Full company profileZhejiang Shapuaisi Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Shapuaisi Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 979M | 939M | 607M | 516M | 347M | 630M | 550M | 645M | 484M | 463M | 395M |
| Gross Profit | 748M | 724M | 429M | 321M | 189M | 397M | 316M | 357M | 231M | 213M | 173M |
| Operating Income | 234M | 178M | -130M | -11.4M | -199M | 54.9M | 55.6M | 22.0M | -112M | -6.09M | -32.5M |
| EBITDA | 369M | 237M | -57.7M | 72.9M | 13.1M | 106M | 114M | 100M | -43.1M | -161M | -80.2M |
| Net Income | 276M | 146M | -126M | 7.86M | -179M | 35.7M | 44.8M | 25.4M | -123M | -239M | -87.1M |
| EPS | 0.93 | 0.45 | -0.39 | 0.02 | -0.56 | 0.11 | 0.14 | 0.07 | -0.33 | -0.64 | -0.23 |
| Balance Sheet | |||||||||||
| Total Assets | 1.84B | 1.87B | 1.65B | 1.59B | 1.67B | 1.59B | 1.96B | 2.17B | 2.11B | 1.87B | 1.75B |
| Total Liabilities | 248M | 212M | 167M | 100M | 367M | 233M | 241M | 441M | 517M | 521M | 464M |
| Shareholders' Equity | 1.59B | 1.66B | 1.48B | 1.49B | 1.31B | 1.35B | 1.71B | 1.72B | 1.59B | 1.35B | 1.29B |
| Cash & Short-term Investments | 485M | 438M | 145M | 483M | 357M | 244M | 554M | 369M | 190M | 112M | 86.8M |
| Total Debt | - | - | - | - | 8.04M | 37.6M | 39.7M | 157M | 242M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 294M | 45.6M | 100M | 59.5M | 44.1M | 101M | 116M | 41.5M | 25.7M | 44.9M | - |
| Capital Expenditure | 39.9M | 114M | 58.4M | 20.3M | 17.2M | 153M | 149M | 220M | 128M | 94.2M | 87.7M |
| Free Cash Flow | 254M | -68.4M | 42.0M | 39.1M | 26.9M | -52.7M | -33.0M | -178M | -102M | -49.2M | -50.6M |
| Ratios | |||||||||||
| ROE | 17.3% | 8.8% | -8.5% | 0.5% | -13.7% | 2.6% | 2.6% | 1.5% | -7.8% | -17.7% | -6.8% |
| ROA | 15.0% | 7.8% | -7.7% | 0.5% | -10.7% | 2.2% | 2.3% | 1.2% | -5.9% | -12.8% | -5.0% |
| Net Profit Margin | 28.2% | 15.6% | -20.8% | 1.5% | -51.7% | 5.7% | 8.1% | 3.9% | -25.5% | -51.6% | -22.0% |
| Debt to Equity | - | - | - | - | 0.01x | 0.03x | 0.02x | 0.09x | 0.15x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Shapuaisi Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.42%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 13, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 7.94M | 0.02 | - |
| 2024 | CNY 14.5M | 0.04 | - |
| 2023 | CNY 13.8M | 0.04 | 54.2% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | CNY 3.55M | 0.01 | - |
| 2019 | CNY 3.55M | 0.01 | 45.2% |
| 2018 | CNY 49.6M | 0.15 | - |
| 2017 | CNY 83.3M | 0.26 | 56.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jun 8, 2018.
Who owns Zhejiang Shapuaisi Pharmaceutical Co Ltd
- Insiders 49.32%
- Institutions 2.42%
- Public & others 48.27%
- Shares outstanding 373M
- Free float 206M
Zhejiang Shapuaisi Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Shapuaisi Pharmaceutical Co Ltd
- Ticker
- 603168.SHG
- ISIN
- CNE100001TG0
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,142
- Fiscal year end
- December
- Address
- No. 1588 Xinming Road, Pinghu, China, 314200
- Phone
- 86 57 38502 1168
- Website
- zjspas.com
About Zhejiang Shapuaisi Pharmaceutical Co Ltd
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antimicrobials, gynecology, and other classes. It offers its products in injections, oral solutions, eye drops, large-volume injections, oral solutions, tablets, granules, and other dosage forms. It also offers medical and health care, and scientific research and teaching facilities. Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. was founded in 2000 and is based in Pinghu, China.
Zhejiang Shapuaisi Pharmaceutical Co Ltd management
4- Mr. Hong Li LinGM & Chairman · born 1993
- Mr. Xiusong LinDeputy GM, Financial Director, Director & Accounting Supervisor · born 1969
- Mr. Mingxiong HuangBoard Secretary & Director · born 1993
- Mr. Hong Sheng XuDeputy General Manager · born 1982